Biocon informs about notification

01 Apr 2024 Evaluate

Biocon has informed that it enclosed notification: 'Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda®) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity. This is further to our previous intimation of 27th March, 2024, informing that approval was received from the MHRA for Liraglutide (gVicotza®), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva. The approvals will further strengthen Biocon’s portfolio of vertically integrated, complex drug products.' The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

368.85 1.50 (0.41%)
24-Mar-2026 13:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1764.10
Dr. Reddys Lab 1256.50
Cipla 1232.00
Zydus Lifesciences 887.05
Lupin 2341.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×